Pfizer said in a press release that in a late-stage trial of more than 2,200 adolescents in the United States, none of the vaccinated people contracted COVID-19. The results indicate that the Pfizer-BioNTech vaccine may be more effective in children between 12 and 15 years of age than in adults.
Pfizer has not yet released the test data. The company plans to submit the results to the FDA in the next few weeks. CEO Albert Bourla said, “I hope to start vaccinating this age group before the start of the next academic year.”
If emergency authorization is obtained, Pfizer’s vaccine will be the first vaccine available in the United States to children under 16 years of age.Public health expert Believe Vaccinating children is crucial to achieving “herd immunity”-when so many people are immune to COVID-19 that the virus can no longer spread effectively. President Joe Biden called for immunization of high school students before the fall of the United States, and immunization of elementary school students in early 2022, provided that Pfizer’s announced test results show that the vaccine is indeed safe and effective.
Pfizer said that trials have shown that the vaccine is safe in children aged 12 to 15, and its side effects are “basically consistent with those observed in participants aged 16 to 25.”
Pfizer’s vaccine First authorized emergency use Targeting people 16 years and older in December, more than 75 million doses have been given to Americans since then.A kind Clinical Trials It was discovered last fall that it was 95% effective in reducing adult COVID-19 infection; a recent study showed thatreal world“From its authorization.
In the announcement, Pfizer also stated that it has begun vaccinating children between 5 and 11 years old in a related global trial, and will start vaccinating a group of children between 2 and 5 years old next week.